133 related articles for article (PubMed ID: 35785606)
1. Combination of CDX2 H-score quantitative analysis with CD3 AI-guided analysis identifies patients with a good prognosis only in stage III colon cancer.
Derangère V; Lecuelle J; Lepage C; Aoulad-Ben Salem O; Allatessem BM; Ilie A; Bouché O; Phelip JM; Baconnier M; Pezet D; Sebbagh V; Terrebonne E; Bouard G; Jooste V; Bouvier AM; Molimard C; Monnien F; Gonzalez D; Le Malicot K; Rageot D; Truntzer C; Bibeau F; Ghiringhelli F;
Eur J Cancer; 2022 Sep; 172():221-230. PubMed ID: 35785606
[TBL] [Abstract][Full Text] [Related]
2. Quantitative analysis of CDX2 protein expression improves its clinical utility as a prognostic biomarker in stage II and III colon cancer.
den Uil SH; de Wit M; Slebos RJC; Delis-van Diemen PM; Sanders J; Piersma SR; Pham TV; Coupé VMH; Bril H; Stockmann HBAC; Jimenez CR; Meijer GA; Fijneman RJA
Eur J Cancer; 2021 Feb; 144():91-100. PubMed ID: 33341450
[TBL] [Abstract][Full Text] [Related]
3. Sidedness Matters: Surrogate Biomarkers Prognosticate Colorectal Cancer upon Anatomic Location.
Ben-Aharon I; Goshen-Lago T; Sternschuss M; Morgenstern S; Geva R; Beny A; Dror Y; Steiner M; Hubert A; Idelevich E; Shulman K; Mishaeli M; Man S; Liebermann N; Soussan-Gutman L; Brenner B
Oncologist; 2019 Aug; 24(8):e696-e701. PubMed ID: 30755502
[TBL] [Abstract][Full Text] [Related]
4. CDX2 prognostic value in stage II/III resected colon cancer is related to CMS classification.
Pilati C; Taieb J; Balogoun R; Marisa L; de Reyniès A; Laurent-Puig P
Ann Oncol; 2017 May; 28(5):1032-1035. PubMed ID: 28328000
[TBL] [Abstract][Full Text] [Related]
5. Artificial intelligence-guided tissue analysis combined with immune infiltrate assessment predicts stage III colon cancer outcomes in PETACC08 study.
Reichling C; Taieb J; Derangere V; Klopfenstein Q; Le Malicot K; Gornet JM; Becheur H; Fein F; Cojocarasu O; Kaminsky MC; Lagasse JP; Luet D; Nguyen S; Etienne PL; Gasmi M; Vanoli A; Perrier H; Puig PL; Emile JF; Lepage C; Ghiringhelli F
Gut; 2020 Apr; 69(4):681-690. PubMed ID: 31780575
[TBL] [Abstract][Full Text] [Related]
6. CDX2 as a Prognostic Biomarker in Stage II and Stage III Colon Cancer.
Dalerba P; Sahoo D; Paik S; Guo X; Yothers G; Song N; Wilcox-Fogel N; Forgó E; Rajendran PS; Miranda SP; Hisamori S; Hutchison J; Kalisky T; Qian D; Wolmark N; Fisher GA; van de Rijn M; Clarke MF
N Engl J Med; 2016 Jan; 374(3):211-22. PubMed ID: 26789870
[TBL] [Abstract][Full Text] [Related]
7. CDX2 and Muc2 immunohistochemistry as prognostic markers in stage II colon cancer.
Cecchini MJ; Walsh JC; Parfitt J; Chakrabarti S; Correa RJ; MacKenzie MJ; Driman DK
Hum Pathol; 2019 Aug; 90():70-79. PubMed ID: 31121192
[TBL] [Abstract][Full Text] [Related]
8. An exploration of immunohistochemistry-based prognostic markers in patients undergoing curative resections for colon cancer.
Bennedsen ALB; Cai L; Hasselager RP; Özcan AA; Mohamed KB; Eriksen JO; Eiholm S; Bzorek M; Fiehn AK; Hviid TVF; Gögenur I
BMC Cancer; 2022 Jan; 22(1):62. PubMed ID: 35027037
[TBL] [Abstract][Full Text] [Related]
9. Mismatch repair phenotype determines the implications of tumor grade and CDX2 expression in stage II-III colon cancer.
Hestetun KE; Aasebø K; Rosenlund NB; Müller Y; Dahl O; Myklebust MP
Mod Pathol; 2021 Jan; 34(1):161-170. PubMed ID: 32737450
[TBL] [Abstract][Full Text] [Related]
10. Prognostic, predictive, and pharmacogenomic assessments of CDX2 refine stratification of colorectal cancer.
Bruun J; Sveen A; Barros R; Eide PW; Eilertsen I; Kolberg M; Pellinen T; David L; Svindland A; Kallioniemi O; Guren MG; Nesbakken A; Almeida R; Lothe RA
Mol Oncol; 2018 Sep; 12(9):1639-1655. PubMed ID: 29900672
[TBL] [Abstract][Full Text] [Related]
11. Prognostic impact of CDX2 in stage II colon cancer: results from two nationwide cohorts.
Hansen TF; Kjær-Frifeldt S; Eriksen AC; Lindebjerg J; Jensen LH; Sørensen FB; Jakobsen A
Br J Cancer; 2018 Nov; 119(11):1367-1373. PubMed ID: 30425348
[TBL] [Abstract][Full Text] [Related]
12. Detection of postoperative plasma circulating tumour DNA and lack of CDX2 expression as markers of recurrence in patients with localised colon cancer.
Tarazona N; Gimeno-Valiente F; Gambardella V; Huerta M; Roselló S; Zuniga S; Calon A; Carbonell-Asins JA; Fontana E; Martinez-Ciarpaglini C; Eason K; Rentero-Garrido P; Fleitas T; Papaccio F; Moro-Valdezate D; Nyamundanda G; Castillo J; Espí A; Sadanandam A; Roda D; Cervantes A
ESMO Open; 2020 Sep; 5(5):e000847. PubMed ID: 32967918
[TBL] [Abstract][Full Text] [Related]
13. Prognostic significance of MUC2, CDX2 and SOX2 in stage II colorectal cancer patients.
Ribeirinho-Soares S; Pádua D; Amaral AL; Valentini E; Azevedo D; Marques C; Barros R; Macedo F; Mesquita P; Almeida R
BMC Cancer; 2021 Apr; 21(1):359. PubMed ID: 33823840
[TBL] [Abstract][Full Text] [Related]
14. Cancer-associated fibroblast-derived exosomal microRNA-24-3p enhances colon cancer cell resistance to MTX by down-regulating CDX2/HEPH axis.
Zhang HW; Shi Y; Liu JB; Wang HM; Wang PY; Wu ZJ; Li L; Gu LP; Cao PS; Wang GR; Ma YS; Fu D
J Cell Mol Med; 2021 Apr; 25(8):3699-3713. PubMed ID: 33621425
[TBL] [Abstract][Full Text] [Related]
15. CDX2 Loss With Microsatellite Stable Phenotype Predicts Poor Clinical Outcome in Stage II Colorectal Carcinoma.
Slik K; Turkki R; Carpén O; Kurki S; Korkeila E; Sundström J; Pellinen T
Am J Surg Pathol; 2019 Nov; 43(11):1473-1482. PubMed ID: 31490234
[TBL] [Abstract][Full Text] [Related]
16. Combination of CDX2 expression and T stage improves prognostic prediction of colorectal cancer.
Xu W; Zhu Y; Shen W; Ding W; Wu T; Guo Y; Chen X; Zhou M; Chen Y; Cui L; Du P
J Int Med Res; 2019 May; 47(5):1829-1842. PubMed ID: 30616445
[TBL] [Abstract][Full Text] [Related]
17. Predictive modelling for high-risk stage II colon cancer using auto-artificial intelligence.
Ishizaki T; Mazaki J; Enomoto M; Udo R; Tago T; Kasahara K; Nagakawa Y
Tech Coloproctol; 2023 Mar; 27(3):183-188. PubMed ID: 36031650
[TBL] [Abstract][Full Text] [Related]
18. CDX2 expression and perioperative patient serum affects the adhesion properties of cultured colon cancer cells.
Davidsen J; Jessen SB; Watt SK; Larsen S; Dahlgaard K; Kirkegaard T; Gögenur I; Troelsen JT
BMC Cancer; 2020 May; 20(1):426. PubMed ID: 32408894
[TBL] [Abstract][Full Text] [Related]
19. Association of CDX2 and mucin expression with chemotherapeutic benefits in patients with stage II/III gastric cancer.
Gao X; Han W; Chen L; Li H; Zhou F; Bai B; Yan J; Guo Y; Liu K; Li W; Li R; Yuan Q; Zhang J; Lu Y; Zhao X; Ji G; Li M; Zhao Q; Wu K; Li Z; Nie Y
Cancer Med; 2023 Sep; 12(17):17613-17631. PubMed ID: 37602699
[TBL] [Abstract][Full Text] [Related]
20. Prognostic Utility of Immunoprofiling in Colon Cancer: Results from a Prospective, Multicenter Nodal Ultrastaging Trial.
Flaherty DC; Lavotshkin S; Jalas JR; Torisu-Itakura H; Kirchoff DD; Sim MS; Lee DJ; Bilchik AJ
J Am Coll Surg; 2016 Jul; 223(1):134-40. PubMed ID: 27282965
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
